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This study aimed to evaluate the prevalence of sexually transmitted infections (STIs)
and associated risk factors in HIV-infected pregnant women followed for prenatal care
in Salvador, Bahia. This was a cross-sectional study of 63 women seeking prenatal care
at a reference center. Participants were interviewed regarding socio-epidemiological and
clinical history, and were tested for HBsAg, anti-HCV, anti HTLV I/II, VDRL, Chlamydia tracho-
matis, Neisseria gonorrhoeae, Mycoplasma hominis, Ureaplasma urealyticum, CD4 count, and HIV
plasma viral load. The main outcome variable was the presence of any STI. The mean age
of patients was 28.2 years (16-40 years). 23 (36.5%) were diagnosed with at least one STI. The
frequency of diagnoses was: HBV, 3.2%; HCV, 8.1%; HTLV I/II, 3.4%; syphilis, 9.5%; Chlamy-
dia trachomatis, 11.1%; HPV, 15.0%; Mycoplasma hominis, 2.1%, and Ureaplasma urealyticum,
2.1%. No case of Neisseria gonorrhoeae was identiﬁed. No association was found between
socio-epidemiological variables and the presence of an STI. CD4 T lymphocyte <500 cells/L
(p=0.047) and plasma viral load >1,000 copies (p = 0.027) were associated with the presenceof STI. STIs are frequent in pregnantwomen infectedwithHIV, and all HIV-infected pregnant
women should be screened to decrease transmission of these pathogens and to protect their
own health.
Pregnant women are at increased risk of STIs due to
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exually transmitted infections (STIs) have been shown
o increase the risk of acquiring and transmitting human
mmunodeﬁciency virus (HIV) infection.1 In women this asso-
iation has been principally observed in the presence of
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Este é um artigo Open Access sob a licençagenital ulcer disease and cervicitis, which disrupt the epithe-
lial barrier, cause local inﬂammation, and increase genital
tract viral load.1,2tência e Pesquisa (CEDAP), Rua Comendador José Alves Ferreira,
physiological changes that accompany pregnancy, such as
congestion of the cervix, edema of the vaginal mucosa, and
alterations in the vaginal ﬂora.3 Additionally, pregnantwomen
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Table 1 – Prevalence of STI in HIV-infected pregnant
women, CEDAP, Salvador, BA, Brazil, 2010-2011.
Sexually transmitted infection %
HPV* 15.0%
Chlamydia trachomatis 11.1%
Syphilis 9.5%
HCV 8.1%
HTLV I/II 3.4%
HBV 3.2%
Mycoplasma hominis 2.1%
Ureaplasma urealyticum 2.1%
Neisseria gonorrhoeae 0%
Any STI 36.5%
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may be less likely to have partners that use condoms, and may
have fewer options to leave unsafe relationships.4 STI in preg-
nancy is associated with increased neonatal morbidity and
mortality and can cause premature labor, low birth weight,
stillbirth, premature rupture of membranes, and severe con-
genital infections.5 In pregnant women infected with HIV, STI
co-infection can increase the risk of vertical transmission of
HIVandother pathogens.6 This risk is particularly pronounced
if the HIV infection is acquired during pregnancy.7
Some STIs are curable, and treatment can be administered
during pregnancy.8 Viral infections, such as hepatitis B and C,
human papillomavirus (HPV) and HIV itself, although not cur-
able, can be treated, and there are measures to control viremia
that can be implemented during pregnancy. Early diagnosis
of these infections can make a difference in the evolution of
pregnancy and prognosis.5
In Brazil, several studies have estimated the prevalence of
STIs in low- or medium-risk pregnant women, but there are
few data on the prevalence of STIs among women already
infected with HIV.9 The prevalence of STIs and associated risk
factors were evaluated in pregnant HIV-infected women at a
public-sector specialty clinic in Salvador, Bahia, Brazil.
Methods
This was a cross-sectional study at the Centro Estadual Espe-
cializado em Diagnóstico, Assistência e Pesquisa (CEDAP)
in Salvador, capital of the state of Bahia, conducted from
October 1, 2010 to September 30, 2011. CEDAP is the main
reference center for high-risk prenatal care of HIV-infected
pregnant women in Salvador. Approximately 85 pregnant
women attend the CEDAP annually.
The Research Ethics Committee of the Bahia State Health
Secretary (Comitê de Ética em Pesquisa da Secretaria de Saúde do
Estado da Bahia (CEP/SESAB) reviewed and approved the study
(protocol number 25/2010).
HIV-infected pregnant women attending CEDAP during the
study periodwho agreed to participatewere included. Patients
who had used antibiotics in the prior 30 days, who presented
with obstetrical complications at the ﬁrst visit, such as threat-
ened abortion, premature labor or premature rupture of the
membranes, and those who had only one consultation were
excluded from the study.
Data were collected at the ﬁrst prenatal consultation
in a private interview room. The participants of the study
signed an informed consent. Questionnaires included socio-
demographic, economic and clinical data, which included
gestational age; age at ﬁrst pregnancy; age at ﬁrst intercourse;
date of HIV diagnosis; alcohol, tobacco or drug use; number
of sexual partners and prior history of STI. Patients were eval-
uated according to Ministry of Health’s guidelines;10 during
the physical examination, cervicovaginal smears were col-
lected for STI diagnosis and cervical cytology. During the same
visit, blood was drawn for serological tests, CD4 cell count,
and plasma viral load determination. All patientswere treated
syndromically for STIs during the ﬁrst prenatal visit, and were
subsequently treated based on laboratory diagnoses.
Patients’ serum was tested using commercially available
kits for hepatitis B surface antigen (HBsAg) (ETI-MAK-4,e Pesquisa; *Cytological alterations – low-grade squamous intraep-
ithelial lesion.
Diasorin - SãoPaulo, Brazil), hepatitis C antibody (HCV) (Murex,
Generlabs Diagnostic - São Paulo, Brazil), and antibodies to
human T-lymphotropic virus types I and II (HTLV I/II) (Sym-
biosis, ALKA Tecnologia - São Paulo, Brazil). VDRL (Wama
- São Carlos, Brazil) was used to screen for syphilis and
titered results were provided. CD4 cell levels were deter-
mined using ﬂow cytometry (Facscalibur, Becton Dickinson -
California, USA); plasma viral load was determined using VER-
SANT RNA 3.0 (Siemens Health Care Diagnostics - Munich,
Germany). Endocervical specimens were cultured on Thayer-
Martin medium for Neisseria gonorrhoeae, and on A7B and
U10 culture media for Mycoplasma hominis and Ureaplasma
urealyticum. Endocervical specimens were also tested for
Chlamydia trachomatis using hybrid capture techniques (QIA-
GEN – São Paulo, Brazil). Cytological alterations corresponding
to viral infection by HPV were identiﬁed by Papanicolaou
smear.
The primary outcome variables were presence of a posi-
tive anti-HTLV I/II, AgHbs, anti-HCV, VDRL; positive capture
hybrid for Chlamydia trachomatis; positive culture for Neisse-
ria gonorrheae, Mycoplasma hominis or Ureaplasma urealyticum or
abnormal Pap smear. An outcomevariablewas constructed for
any positive STI test. Associations between predictor variables
and both the composite outcome variables were evaluated
using the chi-squared test, Fisher’s exact test, and, for con-
tinuous variables, Student’s t-test. Continuous variables were
characterized by means and standard deviations for normally
distributed variables, and bymedians and interquartile ranges
for variables that were not normally distributed. The Statisti-
cal Package for Social Sciences (SPSS) version 17.0 (SPSS Inc. –
Chicago, USA) was used for all statistical testing.
Results
This study evaluated 63 pregnant women infected with HIV.
The mean age of participants was 28.2 years (range 16-40
years); ﬁve (8.1%) were 18 years of age or less. 51 (82.3%)
participants reported that they were married or in a stable
relationship. The large majority (95.2%) of patients self-
identiﬁed as being either of African or mixed ancestry. The
mean gestational age at ﬁrst consultation was 19 weeks. Over-
all, the mean CD4 count was 563 cells/L, and the median
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Table 2 – Risk factors for acute and chronic STIa by demographic and clinical factors, HIV-infected pregnant women,
CEDAP, Salvador, BA, Brazil, 2010–2011.
Risk factor Any STI PR 95% CI p
Present n (%) Absent n (%)
Age
≤ 20 years old 1 (14.3) 6 (85.7) 0.065b
> 20 and ≤ 30 years old 11 (32.4) 23 (67.6)
> 40 and ≤ 40 years old 11 (50.0) 11 (50.0)
Marital status
Married or stable partnership 20 (38.5) 32 (61.5) 1.68 (0.40-7.03) 0.732b
Single 3 (27.3) 8 (72.7)
Educational level
< Fundamental education 16 (40.0) 24 (60.0) 1.52 (0.51-4.53) 0.448
≥ Fundamental education 7 (30.4) 16 (69.4)
Ethnicity
White 0 (0.0) 3 (100.0) 0.730c
Black 12 (41.4) 17 (58.6)
Mixed 11 (35.5) 20 (64.5)
Number of previous deliveries
None 4 (22.2) 14 (77.8) 0.38 (0.11-1.33) 0.121
≥ 1 19 (43.2) 25 (56.8)
Age at ﬁrst sexual intercourse
≤ 14 years 6 (27.3) 16 (72.7) 0.51 (0.16-1.57) 0.235
>14 years 17 (42.5) 23 (57.5)
Number of sexual partners
<10 17 (40.5) 25 (59.5) 1.47 (0.47-4.64) 0.507
≥ 10 6 (31.6) 13 (68.4)
Alcohol use
Yes 11 (45.8) 13 (54.2) 1.90 (0.67-5.45) 0.228
No 12 (30.8) 27 (69.2)
Illicit drug use
Yes 3 (30.0) 7 (70.0) 0.71 (0.16-3.05) 0.734b
No 20 (37.7) 33 (62.3)
Prior history of STI
Yes 13 (46.4) 15 (53.6) 2.17 (0.76-6.15) 0.144
No 10 (28.6) 25 (71.4)
CD4 lymphocyte count
≤ 500 cells/L 14 (50.0) 14 (50.0) 2.89 (1.00-8.34) 0.047
>500 cells/L 9 (25.7) 26 (74.3)
Plasma viral load
<1,000 copies/mL 5 (20.0) 20 (80.0) 0.28 (0.09-0.89) 0.027
≥ 1,000 copies/mL 18 (47.4) 20 (52.6)
CEDAP, CEDAP, Centro Estadual Especializada em Diagnóstico, Assistência e Pesquisa; PR, prevalence ratio; 95% CI, 95% conﬁdence interval.
a Any sexually transmitted infections: N. gonorrhoeae, C. trachomatis, VDRL positive, M. hominis or U. urealyticum,HTLV I/II, HBsAg, HCV, abnormal
cervical cytology.
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nb Fisher’s exact test.
c Linear-by-linear association.
lasma viral load was 2,651 copies/mL. 19 (30.2%) participants
ad fewer than 350 cells/L. 25 (39.7%) had plasma viral loads
ewer than 1,000 copies/mL, and 24 (38.1%) were on antiretro-
iral therapy before pregnancy.
Patients reported a variety of risk factors. 24 (38.1%)
eported alcohol use, of whom 20 (31.7%) reported drink-
ng alcohol only on weekends, three (4.8%) during the week,
nd one (1.6%) daily. The large majority of participants (55,
7.3%) reported not smoking, and ten (15.9%) reported using
on-parenteral illicit drugs (marijuana, crack, or cocaine). Nopatient reported injectable drug use. The mean age at ﬁrst
intercourse was 15.2 years, and almost one-third of partici-
pants began having sexual intercourse at 14 years of age or
less. 23 (37.1%) had had their ﬁrst pregnancy at 18 years of
age or younger. The lifetime reported number of sexual part-
ners ranged from one to 500; 34.5% reported three or fewer
lifetime partners, and 34.5% reported four to nine. 28 (44.4%)
participants also reported a prior history of STI.
Evidence of STI was found in 23 (36.5%) patients. Regarding
STI from serological results, prevalence of 3.2% (2/63) of HBsAg
i s . 20
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positive, 8.1% (5/62) anti-HCV, 9.5% (6/63) of VDRL reagent,
and 3.4% (2/59) anti-HTLV reagent were found. For cervicitis
due to Chlamydia trachomatis diagnosed through hybrid cap-
ture, 11.1% (7/63) were positive, 2.1% (1/48) of cultures were
positive for Mycoplasma hominis, 2.1% (1/48) were positive for
Ureaplasma urealyticum, and there were no positive results for
Neisseria gonorrhoeae. The presence of cytological alterations,
which were described as low-grade squamous intraepithelial
lesion, was observed in 15.0% (9/60) patients (Table 1). Six
(9.5%) patients had more than one STI.
No association was found between socio-epidemiological
variables and presence of STI. CD4 T lymphocyte count < 500
cells/L (p=0.047) and plasma viral load> 1000 copies/mL
(p=0.027) were associated with the presence of an STI
(Table 2).
Discussion
36.5% of HIV-infected pregnant women in our sample were
found to have another STI. This is an enormous STI burden
in a highly vulnerable population. The prevalence of infection
with individual agents found in this study was in general sub-
stantially higher than that reported in the general population
of pregnant women in Brazil, as 0.88% for HTLV I/II,11 1.8% for
hepatitis B,12 1.4% for HCV,13 3.9% for syphilis,11 9.8% for C.
trachomatis14 and 1.5% for N. gonorrhoeae.15 However, a recent
study on a population of pregnant women with HIV infection
in Southern Brazil found that 50% of women were infected
with HBV, HCV, syphilis, or HPV.16 Rates of bacterial STI sim-
ilar to those found in the present study were reported in a
study conducted in Kenya, but in that study the investigators
also reported very high prevalence of bacterial vaginosis and
trichomoniasis (37% and 16%, respectively), which were not
assessed in the present study.17 In Europe, 24.5% of pregnant
HIV-infected women had one or more STI; syphilis was the
most common bacterial STI (2.0%), and HPV-related warts
were found in 8.6% in that study.18 These ﬁndings alone rein-
force the need for early diagnosis of STI in this population to
avoid additional obstetrical and neonatal complications.
In this population, no association of STI with the risk fac-
tors considered associatedwith the presence of STIwas found,
such as sexual activity at ≤ 14 years (p=0.235), more than ten
sexual partners (p=0.507), alcohol use (p=0.228), illicit drug
use (p=0.734), and previous history of STI (p = 0.144), which
have been previously found in HIV-uninfected women.19 The
lack of associationwith socio-demographic and economic fac-
tors suggest that there is not a speciﬁc subgroup that should be
evaluated; all HIV-infected pregnant women are at increased
risk for STI.
In contrast to other studies, the principal risk factor for
STI found in this study was having a CD4 lymphocytes count
< 500 cells/L (p=0.047) and an elevated HIV plasma viral load
(p = 0.027).17 It is possible that this ﬁnding of high STI preva-
lence may represent failure of a deteriorating immune system
to clear some of these infections. This association was found
18by other authors, suggesting that compromised immunity
associated with the presence of STI could also be explained
by the difﬁculty of obtaining early diagnosis and appropri-
ate treatment. 17.5% of pregnant women in this study had12;16(6):581–585
CD4 counts <200 cells/L, which is the deﬁnition of acquired
immunodeﬁciency syndrome (AIDS) according to the Centers
forDiseaseControl andPrevention (CDC,USA) criteria;20 this is
a strong indication of poor access and inadequate monitoring.
The present study has some limitations. First, it was dif-
ﬁcult to enroll women in the present study; many found
a speculum examination during pregnancy to be culturally
unacceptable. Some women did not return to continue pre-
natal care. This potentially created non-participation and
selection bias, and also may have led to a loss of statistical
power. Moreover, while hepatitis B, hepatitis C, and HTLV I/II
were classiﬁed as STIs, they are also transmitted parenterally
and during labor and delivery; however, these routes of trans-
mission were evaluated. Finally, this study was conducted in a
public clinic in a city inNortheastern Brazil, with a small num-
ber of pregnant women; how these ﬁndings will generalize to
the rest of the country is not clear.
Conclusion
Ahigh STI burdenwas found inpregnantHIV-infectedwomen.
There is a clear need for early diagnosis of these infections
in pregnancy, in order to prevent complications and vertical
transmission. It is suggested that additional large studies be
conducted in other regions of Brazil in order to understand the
epidemiology of STIs in this speciﬁc population, and to imple-
ment the most effective prevention policies based on these
ﬁndings.
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